0

Close
 
Upcoming Allied Market Research
2023
Image-guided Biopsy Market

Image-Guided Biopsy Market

by Technology (X- Ray, Ultrasound, Mammography, CT, MRI), by Process (Fine Needles, Core Needles, Vacuum-assisted Biopsy) and by End User (Hospitals, Ambulatory Surgical Centers, Clinics, Research and Academic Institutes): Global Opportunity Analysis and Industry Forecast, 2023-2032

LS : Diagnostics and Biotech
Report Code: A15448
Nov 2023 | Pages: NA
Tables: NA
Charts: NA

  • Formats*:

  • pdf

    Single User License, Five User
    License & Enterprise User License

  • xls

    Data Pack Excel License

  • ppt

    It comes with the additional cost
    of $2500.00 contact sales.
 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Image-guided Biopsy Market

Request Now !

Image-guided biopsy uses imaging technologies to examine the inside of the body. The biopsy allows the medical expert to readily obtain a sample of the suspicious cell by inserting the needle into the optimum position. It is regarded as one of the greatest methods of collecting samples because it produces no significant harm. As pictures are required to guide the placement of the needle during a biopsy, this technique is often performed in one of the two locations, such as in the Interventional Radiology (IR) suite using ultrasound (sound waves) or fluoroscopy (X-rays), or in the CT room with a CT scanner.

COVID-19 Impact Analysis

Globally, the COVID-19 pandemic has impacted routine hospital services. Elective procedures are being reduced significantly in order to reduce the risk of infection and to transform operating rooms into COVID-19 emergency facilities. The vast majority of participants cancelled planned appointments, routine check-ups, or chronic condition treatment. To resume elective procedures, various safety standards must be followed, such as maintaining sanitation, isolating patients before and after surgery, and testing patients for COVID-19 before they are admitted for the surgery. Delaying routine or preventative screenings was acceptable during the pandemic's beginning stage, especially with patients using efficient telemedicine services. As a result, COVID-19 is expected to have a substantial impact on the image-guided biopsy market.


Top Impacting Factors

  • One of the primary factors to drive the growth of the image-guided biopsy market is the rise in the occurrences of chronic diseases such as cancer among the global population.
  • Initiatives done by the government and health organizations globally to raise disease awareness and promote R&D activities to improve treatment facilities accelerate the expansion of the image-guided biopsy market.
  • The rise in the preference for less invasive procedures due to factors such as the low risk of injury and increased awareness of the benefits of early diagnosis has a positive impact on the image-guided biopsy market.
  • Furthermore, the aging population, the increase in public awareness of diseases and treatment choices, improved healthcare infrastructure, the increase in investment, and he rise in healthcare expenditure, all have a beneficial impact on the image-guided biopsy market.
  • Furthermore, technological advances and innovations are expected to provide profitable chances to image-guided biopsy market players during the forecast period.
  • On the other hand, the rise in concerns about the danger of infection involved with the use of aspiration and biopsy needles is projected to hamper the expansion of the image-guided biopsy market.

Market Trends

New Product Launches to Flourish Image-guided Biopsy Market 

In January 2019, IZI Medical Products acquired Cook Medical’s soft tissue biopsy and breast localization needle product line.

In February 2018, Merit Medical Systems, Inc. announced the closure of its purchase of divestment assets from BD (Becton, Dickinson, and Company).

In September 2018, EZ Shot 3 Plus 25 G EUS single-use needle, developed by Olympus Corporation for fine-needle biopsy and aspiration, received a FDA approval. The needle can be used to study submucosal and extramural lesions found in various sections of the gastrointestinal tract. Merit Medical Systems Inc. launched five new manual bone biopsy systems for upper-spine, deep-bone, and narrow-access procedures in the same month.

The rise in incidences of cancer is the most important factor to drive the growth of the image-guided biopsy market. According to the World Health Organization (WHO), 21.4 million more patients will be diagnosed with malignant tumors in 2030, up from 12.7 million in 2008. Furthermore, cancer took the lives of 9.6 million people globally in 2018. Biopsy and aspiration are commonly used to explore the nature of tumors by removing a portion of the tissue or fluid in concern and analyze it. With the rising cancer burden, healthcare professionals and government agencies are stepping up efforts to deliver improved diagnostic services, leading to an increase in demand for the image-guided biopsy market.

Key Benefits of Report

  • This study presents the analytical depiction of the image-guided biopsy market along with the current trends and future estimations to determine the imminent investment pockets.
  • The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the image-guided biopsy market share.
  • The current market is quantitatively analyzed to highlight the image-guided biopsy market growth scenario.
  • Porter’s five forces analysis illustrates the potency of buyers & suppliers in the image-guided biopsy market. 
  • The report provides a detailed image-guided biopsy market analysis based on competitive intensity and how the competition will take shape in coming years.

Questions Answered in Image-Guided Biopsy Market Report

  • Who are the leading market players active in the image-guided biopsy market?
  • What current trends will influence the image-guided biopsy market in the next few years?
  • What are the driving factors, restraints, and opportunities in the image-guided biopsy market?
  • What future projections would help in taking further strategic steps?
  • What is image-guided biopsy?
  • What is the image-guided biopsy market prediction for the future?
  • Who are the leading global players in the image-guided biopsy market?
  • What are the current trends and predicted trends?
  • What are the key benefits of the image-guided biopsy market report?

 Image-Guided Biopsy Market Report Highlights

Aspects Details
By Technology
  • X- Ray
  • Ultrasound
  • Mammography
  • CT
  • MRI
By Process
  • Fine Needles
  • Core Needles
  • Vacuum-assisted Biopsy
By End User
  • Hospitals
  • Ambulatory Surgical Centers
  • Clinics
  • Research and Academic Institutes
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (Germany, France, UK, Italy, Spain, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific)
  • LAMEA  (Brazil, Saudi Arabia, South Africa, Rest of LAMEA)
Key Market Players Hologic Inc., Brainlab, Stryker, GENERAL ELECTRIC, Varian Medical Systems, Inc., Koninklijke Philips N.V., Olympus Corporation, Analogic Corporation, Siemens Healthcare GmbH, Medtronic,, KARL STORZ Endoscopy India Pvt. Ltd.
 

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

    • 3.6. COVID-19 Impact Analysis

  • CHAPTER 4: IMAGE-GUIDED BIOPSY MARKET, BY TECHNOLOGY

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Technology

    • 4.2. X- Ray

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Ultrasound

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

    • 4.4. Mammography

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

    • 4.5. CT

      • 4.5.1. Key Market Trends, Growth Factors and Opportunities

      • 4.5.2. Market Size and Forecast, By Region

      • 4.5.3. Market Share Analysis, By Country

    • 4.6. MRI

      • 4.6.1. Key Market Trends, Growth Factors and Opportunities

      • 4.6.2. Market Size and Forecast, By Region

      • 4.6.3. Market Share Analysis, By Country

  • CHAPTER 5: IMAGE-GUIDED BIOPSY MARKET, BY PROCESS

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Process

    • 5.2. Fine Needles

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Core Needles

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. Vacuum-assisted Biopsy

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

  • CHAPTER 6: IMAGE-GUIDED BIOPSY MARKET, BY END USER

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By End User

    • 6.2. Hospitals

      • 6.2.1. Key Market Trends, Growth Factors and Opportunities

      • 6.2.2. Market Size and Forecast, By Region

      • 6.2.3. Market Share Analysis, By Country

    • 6.3. Ambulatory Surgical Centers

      • 6.3.1. Key Market Trends, Growth Factors and Opportunities

      • 6.3.2. Market Size and Forecast, By Region

      • 6.3.3. Market Share Analysis, By Country

    • 6.4. Clinics

      • 6.4.1. Key Market Trends, Growth Factors and Opportunities

      • 6.4.2. Market Size and Forecast, By Region

      • 6.4.3. Market Share Analysis, By Country

    • 6.5. Research And Academic Institutes

      • 6.5.1. Key Market Trends, Growth Factors and Opportunities

      • 6.5.2. Market Size and Forecast, By Region

      • 6.5.3. Market Share Analysis, By Country

  • CHAPTER 7: IMAGE-GUIDED BIOPSY MARKET, BY REGION

    • 7.1. Market Overview

      • 7.1.1 Market Size and Forecast, By Region

    • 7.2. North America

      • 7.2.1. Key Market Trends and Opportunities

      • 7.2.2. Market Size and Forecast, By Technology

      • 7.2.3. Market Size and Forecast, By Process

      • 7.2.4. Market Size and Forecast, By End User

      • 7.2.5. Market Size and Forecast, By Country

      • 7.2.6. U.S. Image-guided Biopsy Market

        • 7.2.6.1. Market Size and Forecast, By Technology
        • 7.2.6.2. Market Size and Forecast, By Process
        • 7.2.6.3. Market Size and Forecast, By End User

      • 7.2.7. Canada Image-guided Biopsy Market

        • 7.2.7.1. Market Size and Forecast, By Technology
        • 7.2.7.2. Market Size and Forecast, By Process
        • 7.2.7.3. Market Size and Forecast, By End User

      • 7.2.8. Mexico Image-guided Biopsy Market

        • 7.2.8.1. Market Size and Forecast, By Technology
        • 7.2.8.2. Market Size and Forecast, By Process
        • 7.2.8.3. Market Size and Forecast, By End User

    • 7.3. Europe

      • 7.3.1. Key Market Trends and Opportunities

      • 7.3.2. Market Size and Forecast, By Technology

      • 7.3.3. Market Size and Forecast, By Process

      • 7.3.4. Market Size and Forecast, By End User

      • 7.3.5. Market Size and Forecast, By Country

      • 7.3.6. France Image-guided Biopsy Market

        • 7.3.6.1. Market Size and Forecast, By Technology
        • 7.3.6.2. Market Size and Forecast, By Process
        • 7.3.6.3. Market Size and Forecast, By End User

      • 7.3.7. Germany Image-guided Biopsy Market

        • 7.3.7.1. Market Size and Forecast, By Technology
        • 7.3.7.2. Market Size and Forecast, By Process
        • 7.3.7.3. Market Size and Forecast, By End User

      • 7.3.8. Italy Image-guided Biopsy Market

        • 7.3.8.1. Market Size and Forecast, By Technology
        • 7.3.8.2. Market Size and Forecast, By Process
        • 7.3.8.3. Market Size and Forecast, By End User

      • 7.3.9. Spain Image-guided Biopsy Market

        • 7.3.9.1. Market Size and Forecast, By Technology
        • 7.3.9.2. Market Size and Forecast, By Process
        • 7.3.9.3. Market Size and Forecast, By End User

      • 7.3.10. UK Image-guided Biopsy Market

        • 7.3.10.1. Market Size and Forecast, By Technology
        • 7.3.10.2. Market Size and Forecast, By Process
        • 7.3.10.3. Market Size and Forecast, By End User

      • 7.3.11. Russia Image-guided Biopsy Market

        • 7.3.11.1. Market Size and Forecast, By Technology
        • 7.3.11.2. Market Size and Forecast, By Process
        • 7.3.11.3. Market Size and Forecast, By End User

      • 7.3.12. Rest Of Europe Image-guided Biopsy Market

        • 7.3.12.1. Market Size and Forecast, By Technology
        • 7.3.12.2. Market Size and Forecast, By Process
        • 7.3.12.3. Market Size and Forecast, By End User

    • 7.4. Asia-Pacific

      • 7.4.1. Key Market Trends and Opportunities

      • 7.4.2. Market Size and Forecast, By Technology

      • 7.4.3. Market Size and Forecast, By Process

      • 7.4.4. Market Size and Forecast, By End User

      • 7.4.5. Market Size and Forecast, By Country

      • 7.4.6. China Image-guided Biopsy Market

        • 7.4.6.1. Market Size and Forecast, By Technology
        • 7.4.6.2. Market Size and Forecast, By Process
        • 7.4.6.3. Market Size and Forecast, By End User

      • 7.4.7. Japan Image-guided Biopsy Market

        • 7.4.7.1. Market Size and Forecast, By Technology
        • 7.4.7.2. Market Size and Forecast, By Process
        • 7.4.7.3. Market Size and Forecast, By End User

      • 7.4.8. India Image-guided Biopsy Market

        • 7.4.8.1. Market Size and Forecast, By Technology
        • 7.4.8.2. Market Size and Forecast, By Process
        • 7.4.8.3. Market Size and Forecast, By End User

      • 7.4.9. South Korea Image-guided Biopsy Market

        • 7.4.9.1. Market Size and Forecast, By Technology
        • 7.4.9.2. Market Size and Forecast, By Process
        • 7.4.9.3. Market Size and Forecast, By End User

      • 7.4.10. Australia Image-guided Biopsy Market

        • 7.4.10.1. Market Size and Forecast, By Technology
        • 7.4.10.2. Market Size and Forecast, By Process
        • 7.4.10.3. Market Size and Forecast, By End User

      • 7.4.11. Thailand Image-guided Biopsy Market

        • 7.4.11.1. Market Size and Forecast, By Technology
        • 7.4.11.2. Market Size and Forecast, By Process
        • 7.4.11.3. Market Size and Forecast, By End User

      • 7.4.12. Malaysia Image-guided Biopsy Market

        • 7.4.12.1. Market Size and Forecast, By Technology
        • 7.4.12.2. Market Size and Forecast, By Process
        • 7.4.12.3. Market Size and Forecast, By End User

      • 7.4.13. Indonesia Image-guided Biopsy Market

        • 7.4.13.1. Market Size and Forecast, By Technology
        • 7.4.13.2. Market Size and Forecast, By Process
        • 7.4.13.3. Market Size and Forecast, By End User

      • 7.4.14. Rest of Asia Pacific Image-guided Biopsy Market

        • 7.4.14.1. Market Size and Forecast, By Technology
        • 7.4.14.2. Market Size and Forecast, By Process
        • 7.4.14.3. Market Size and Forecast, By End User

    • 7.5. LAMEA

      • 7.5.1. Key Market Trends and Opportunities

      • 7.5.2. Market Size and Forecast, By Technology

      • 7.5.3. Market Size and Forecast, By Process

      • 7.5.4. Market Size and Forecast, By End User

      • 7.5.5. Market Size and Forecast, By Country

      • 7.5.6. Brazil Image-guided Biopsy Market

        • 7.5.6.1. Market Size and Forecast, By Technology
        • 7.5.6.2. Market Size and Forecast, By Process
        • 7.5.6.3. Market Size and Forecast, By End User

      • 7.5.7. South Africa Image-guided Biopsy Market

        • 7.5.7.1. Market Size and Forecast, By Technology
        • 7.5.7.2. Market Size and Forecast, By Process
        • 7.5.7.3. Market Size and Forecast, By End User

      • 7.5.8. Saudi Arabia Image-guided Biopsy Market

        • 7.5.8.1. Market Size and Forecast, By Technology
        • 7.5.8.2. Market Size and Forecast, By Process
        • 7.5.8.3. Market Size and Forecast, By End User

      • 7.5.9. UAE Image-guided Biopsy Market

        • 7.5.9.1. Market Size and Forecast, By Technology
        • 7.5.9.2. Market Size and Forecast, By Process
        • 7.5.9.3. Market Size and Forecast, By End User

      • 7.5.10. Argentina Image-guided Biopsy Market

        • 7.5.10.1. Market Size and Forecast, By Technology
        • 7.5.10.2. Market Size and Forecast, By Process
        • 7.5.10.3. Market Size and Forecast, By End User

      • 7.5.11. Rest of LAMEA Image-guided Biopsy Market

        • 7.5.11.1. Market Size and Forecast, By Technology
        • 7.5.11.2. Market Size and Forecast, By Process
        • 7.5.11.3. Market Size and Forecast, By End User

  • CHAPTER 8: COMPETITIVE LANDSCAPE

    • 8.1. Introduction

    • 8.2. Top Winning Strategies

    • 8.3. Product Mapping Of Top 10 Player

    • 8.4. Competitive Dashboard

    • 8.5. Competitive Heatmap

    • 8.6. Top Player Positioning,2022

  • CHAPTER 9: COMPANY PROFILES

    • 9.1. Koninklijke Philips N.V.

      • 9.1.1. Company Overview

      • 9.1.2. Key Executives

      • 9.1.3. Company Snapshot

      • 9.1.4. Operating Business Segments

      • 9.1.5. Product Portfolio

      • 9.1.6. Business Performance

      • 9.1.7. Key Strategic Moves and Developments

    • 9.2. Siemens Healthcare GmbH

      • 9.2.1. Company Overview

      • 9.2.2. Key Executives

      • 9.2.3. Company Snapshot

      • 9.2.4. Operating Business Segments

      • 9.2.5. Product Portfolio

      • 9.2.6. Business Performance

      • 9.2.7. Key Strategic Moves and Developments

    • 9.3. Analogic Corporation

      • 9.3.1. Company Overview

      • 9.3.2. Key Executives

      • 9.3.3. Company Snapshot

      • 9.3.4. Operating Business Segments

      • 9.3.5. Product Portfolio

      • 9.3.6. Business Performance

      • 9.3.7. Key Strategic Moves and Developments

    • 9.4. GENERAL ELECTRIC

      • 9.4.1. Company Overview

      • 9.4.2. Key Executives

      • 9.4.3. Company Snapshot

      • 9.4.4. Operating Business Segments

      • 9.4.5. Product Portfolio

      • 9.4.6. Business Performance

      • 9.4.7. Key Strategic Moves and Developments

    • 9.5. Varian Medical Systems, Inc.

      • 9.5.1. Company Overview

      • 9.5.2. Key Executives

      • 9.5.3. Company Snapshot

      • 9.5.4. Operating Business Segments

      • 9.5.5. Product Portfolio

      • 9.5.6. Business Performance

      • 9.5.7. Key Strategic Moves and Developments

    • 9.6. Brainlab

      • 9.6.1. Company Overview

      • 9.6.2. Key Executives

      • 9.6.3. Company Snapshot

      • 9.6.4. Operating Business Segments

      • 9.6.5. Product Portfolio

      • 9.6.6. Business Performance

      • 9.6.7. Key Strategic Moves and Developments

    • 9.7. Medtronic,

      • 9.7.1. Company Overview

      • 9.7.2. Key Executives

      • 9.7.3. Company Snapshot

      • 9.7.4. Operating Business Segments

      • 9.7.5. Product Portfolio

      • 9.7.6. Business Performance

      • 9.7.7. Key Strategic Moves and Developments

    • 9.8. Olympus Corporation

      • 9.8.1. Company Overview

      • 9.8.2. Key Executives

      • 9.8.3. Company Snapshot

      • 9.8.4. Operating Business Segments

      • 9.8.5. Product Portfolio

      • 9.8.6. Business Performance

      • 9.8.7. Key Strategic Moves and Developments

    • 9.9. KARL STORZ Endoscopy India Pvt. Ltd.

      • 9.9.1. Company Overview

      • 9.9.2. Key Executives

      • 9.9.3. Company Snapshot

      • 9.9.4. Operating Business Segments

      • 9.9.5. Product Portfolio

      • 9.9.6. Business Performance

      • 9.9.7. Key Strategic Moves and Developments

    • 9.10. Stryker

      • 9.10.1. Company Overview

      • 9.10.2. Key Executives

      • 9.10.3. Company Snapshot

      • 9.10.4. Operating Business Segments

      • 9.10.5. Product Portfolio

      • 9.10.6. Business Performance

      • 9.10.7. Key Strategic Moves and Developments

    • 9.11. Hologic Inc.

      • 9.11.1. Company Overview

      • 9.11.2. Key Executives

      • 9.11.3. Company Snapshot

      • 9.11.4. Operating Business Segments

      • 9.11.5. Product Portfolio

      • 9.11.6. Business Performance

      • 9.11.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL IMAGE-GUIDED BIOPSY MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 2. GLOBAL IMAGE-GUIDED BIOPSY MARKET FOR X- RAY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 3. GLOBAL IMAGE-GUIDED BIOPSY MARKET FOR ULTRASOUND, BY REGION, 2022-2032 ($MILLION)
  • TABLE 4. GLOBAL IMAGE-GUIDED BIOPSY MARKET FOR MAMMOGRAPHY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 5. GLOBAL IMAGE-GUIDED BIOPSY MARKET FOR CT, BY REGION, 2022-2032 ($MILLION)
  • TABLE 6. GLOBAL IMAGE-GUIDED BIOPSY MARKET FOR MRI, BY REGION, 2022-2032 ($MILLION)
  • TABLE 7. GLOBAL IMAGE-GUIDED BIOPSY MARKET, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 8. GLOBAL IMAGE-GUIDED BIOPSY MARKET FOR FINE NEEDLES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 9. GLOBAL IMAGE-GUIDED BIOPSY MARKET FOR CORE NEEDLES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 10. GLOBAL IMAGE-GUIDED BIOPSY MARKET FOR VACUUM-ASSISTED BIOPSY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. GLOBAL IMAGE-GUIDED BIOPSY MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 12. GLOBAL IMAGE-GUIDED BIOPSY MARKET FOR HOSPITALS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 13. GLOBAL IMAGE-GUIDED BIOPSY MARKET FOR AMBULATORY SURGICAL CENTERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 14. GLOBAL IMAGE-GUIDED BIOPSY MARKET FOR CLINICS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 15. GLOBAL IMAGE-GUIDED BIOPSY MARKET FOR RESEARCH AND ACADEMIC INSTITUTES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 16. GLOBAL IMAGE-GUIDED BIOPSY MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 17. NORTH AMERICA IMAGE-GUIDED BIOPSY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 18. NORTH AMERICA IMAGE-GUIDED BIOPSY, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 19. NORTH AMERICA IMAGE-GUIDED BIOPSY, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 20. NORTH AMERICA IMAGE-GUIDED BIOPSY, BY END USER, 2022-2032 ($MILLION)
  • TABLE 21. U.S. IMAGE-GUIDED BIOPSY, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 22. U.S. IMAGE-GUIDED BIOPSY, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 23. U.S. IMAGE-GUIDED BIOPSY, BY END USER, 2022-2032 ($MILLION)
  • TABLE 24. CANADA IMAGE-GUIDED BIOPSY, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 25. CANADA IMAGE-GUIDED BIOPSY, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 26. CANADA IMAGE-GUIDED BIOPSY, BY END USER, 2022-2032 ($MILLION)
  • TABLE 27. MEXICO IMAGE-GUIDED BIOPSY, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 28. MEXICO IMAGE-GUIDED BIOPSY, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 29. MEXICO IMAGE-GUIDED BIOPSY, BY END USER, 2022-2032 ($MILLION)
  • TABLE 30. EUROPE IMAGE-GUIDED BIOPSY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 31. EUROPE IMAGE-GUIDED BIOPSY, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 32. EUROPE IMAGE-GUIDED BIOPSY, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 33. EUROPE IMAGE-GUIDED BIOPSY, BY END USER, 2022-2032 ($MILLION)
  • TABLE 34. FRANCE IMAGE-GUIDED BIOPSY, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 35. FRANCE IMAGE-GUIDED BIOPSY, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 36. FRANCE IMAGE-GUIDED BIOPSY, BY END USER, 2022-2032 ($MILLION)
  • TABLE 37. GERMANY IMAGE-GUIDED BIOPSY, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 38. GERMANY IMAGE-GUIDED BIOPSY, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 39. GERMANY IMAGE-GUIDED BIOPSY, BY END USER, 2022-2032 ($MILLION)
  • TABLE 40. ITALY IMAGE-GUIDED BIOPSY, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 41. ITALY IMAGE-GUIDED BIOPSY, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 42. ITALY IMAGE-GUIDED BIOPSY, BY END USER, 2022-2032 ($MILLION)
  • TABLE 43. SPAIN IMAGE-GUIDED BIOPSY, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 44. SPAIN IMAGE-GUIDED BIOPSY, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 45. SPAIN IMAGE-GUIDED BIOPSY, BY END USER, 2022-2032 ($MILLION)
  • TABLE 46. UK IMAGE-GUIDED BIOPSY, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 47. UK IMAGE-GUIDED BIOPSY, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 48. UK IMAGE-GUIDED BIOPSY, BY END USER, 2022-2032 ($MILLION)
  • TABLE 49. RUSSIA IMAGE-GUIDED BIOPSY, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 50. RUSSIA IMAGE-GUIDED BIOPSY, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 51. RUSSIA IMAGE-GUIDED BIOPSY, BY END USER, 2022-2032 ($MILLION)
  • TABLE 52. REST OF EUROPE IMAGE-GUIDED BIOPSY, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 53. REST OF EUROPE IMAGE-GUIDED BIOPSY, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 54. REST OF EUROPE IMAGE-GUIDED BIOPSY, BY END USER, 2022-2032 ($MILLION)
  • TABLE 55. ASIA-PACIFIC IMAGE-GUIDED BIOPSY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 56. ASIA-PACIFIC IMAGE-GUIDED BIOPSY, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 57. ASIA-PACIFIC IMAGE-GUIDED BIOPSY, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 58. ASIA-PACIFIC IMAGE-GUIDED BIOPSY, BY END USER, 2022-2032 ($MILLION)
  • TABLE 59. CHINA IMAGE-GUIDED BIOPSY, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 60. CHINA IMAGE-GUIDED BIOPSY, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 61. CHINA IMAGE-GUIDED BIOPSY, BY END USER, 2022-2032 ($MILLION)
  • TABLE 62. JAPAN IMAGE-GUIDED BIOPSY, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 63. JAPAN IMAGE-GUIDED BIOPSY, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 64. JAPAN IMAGE-GUIDED BIOPSY, BY END USER, 2022-2032 ($MILLION)
  • TABLE 65. INDIA IMAGE-GUIDED BIOPSY, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 66. INDIA IMAGE-GUIDED BIOPSY, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 67. INDIA IMAGE-GUIDED BIOPSY, BY END USER, 2022-2032 ($MILLION)
  • TABLE 68. SOUTH KOREA IMAGE-GUIDED BIOPSY, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 69. SOUTH KOREA IMAGE-GUIDED BIOPSY, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 70. SOUTH KOREA IMAGE-GUIDED BIOPSY, BY END USER, 2022-2032 ($MILLION)
  • TABLE 71. AUSTRALIA IMAGE-GUIDED BIOPSY, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 72. AUSTRALIA IMAGE-GUIDED BIOPSY, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 73. AUSTRALIA IMAGE-GUIDED BIOPSY, BY END USER, 2022-2032 ($MILLION)
  • TABLE 74. THAILAND IMAGE-GUIDED BIOPSY, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 75. THAILAND IMAGE-GUIDED BIOPSY, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 76. THAILAND IMAGE-GUIDED BIOPSY, BY END USER, 2022-2032 ($MILLION)
  • TABLE 77. MALAYSIA IMAGE-GUIDED BIOPSY, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 78. MALAYSIA IMAGE-GUIDED BIOPSY, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 79. MALAYSIA IMAGE-GUIDED BIOPSY, BY END USER, 2022-2032 ($MILLION)
  • TABLE 80. INDONESIA IMAGE-GUIDED BIOPSY, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 81. INDONESIA IMAGE-GUIDED BIOPSY, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 82. INDONESIA IMAGE-GUIDED BIOPSY, BY END USER, 2022-2032 ($MILLION)
  • TABLE 83. REST OF ASIA PACIFIC IMAGE-GUIDED BIOPSY, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 84. REST OF ASIA PACIFIC IMAGE-GUIDED BIOPSY, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 85. REST OF ASIA PACIFIC IMAGE-GUIDED BIOPSY, BY END USER, 2022-2032 ($MILLION)
  • TABLE 86. LAMEA IMAGE-GUIDED BIOPSY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 87. LAMEA IMAGE-GUIDED BIOPSY, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 88. LAMEA IMAGE-GUIDED BIOPSY, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 89. LAMEA IMAGE-GUIDED BIOPSY, BY END USER, 2022-2032 ($MILLION)
  • TABLE 90. BRAZIL IMAGE-GUIDED BIOPSY, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 91. BRAZIL IMAGE-GUIDED BIOPSY, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 92. BRAZIL IMAGE-GUIDED BIOPSY, BY END USER, 2022-2032 ($MILLION)
  • TABLE 93. SOUTH AFRICA IMAGE-GUIDED BIOPSY, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 94. SOUTH AFRICA IMAGE-GUIDED BIOPSY, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 95. SOUTH AFRICA IMAGE-GUIDED BIOPSY, BY END USER, 2022-2032 ($MILLION)
  • TABLE 96. SAUDI ARABIA IMAGE-GUIDED BIOPSY, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 97. SAUDI ARABIA IMAGE-GUIDED BIOPSY, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 98. SAUDI ARABIA IMAGE-GUIDED BIOPSY, BY END USER, 2022-2032 ($MILLION)
  • TABLE 99. UAE IMAGE-GUIDED BIOPSY, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 100. UAE IMAGE-GUIDED BIOPSY, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 101. UAE IMAGE-GUIDED BIOPSY, BY END USER, 2022-2032 ($MILLION)
  • TABLE 102. ARGENTINA IMAGE-GUIDED BIOPSY, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 103. ARGENTINA IMAGE-GUIDED BIOPSY, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 104. ARGENTINA IMAGE-GUIDED BIOPSY, BY END USER, 2022-2032 ($MILLION)
  • TABLE 105. REST OF LAMEA IMAGE-GUIDED BIOPSY, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 106. REST OF LAMEA IMAGE-GUIDED BIOPSY, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 107. REST OF LAMEA IMAGE-GUIDED BIOPSY, BY END USER, 2022-2032 ($MILLION)
  • TABLE 108. KONINKLIJKE PHILIPS N.V.: KEY EXECUTIVES
  • TABLE 109. KONINKLIJKE PHILIPS N.V.: COMPANY SNAPSHOT
  • TABLE 110. KONINKLIJKE PHILIPS N.V.: OPERATING SEGMENTS
  • TABLE 111. KONINKLIJKE PHILIPS N.V.: PRODUCT PORTFOLIO
  • TABLE 112. KONINKLIJKE PHILIPS N.V.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 113. SIEMENS HEALTHCARE GMBH: KEY EXECUTIVES
  • TABLE 114. SIEMENS HEALTHCARE GMBH: COMPANY SNAPSHOT
  • TABLE 115. SIEMENS HEALTHCARE GMBH: OPERATING SEGMENTS
  • TABLE 116. SIEMENS HEALTHCARE GMBH: PRODUCT PORTFOLIO
  • TABLE 117. SIEMENS HEALTHCARE GMBH: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 118. ANALOGIC CORPORATION: KEY EXECUTIVES
  • TABLE 119. ANALOGIC CORPORATION: COMPANY SNAPSHOT
  • TABLE 120. ANALOGIC CORPORATION: OPERATING SEGMENTS
  • TABLE 121. ANALOGIC CORPORATION: PRODUCT PORTFOLIO
  • TABLE 122. ANALOGIC CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 123. GENERAL ELECTRIC: KEY EXECUTIVES
  • TABLE 124. GENERAL ELECTRIC: COMPANY SNAPSHOT
  • TABLE 125. GENERAL ELECTRIC: OPERATING SEGMENTS
  • TABLE 126. GENERAL ELECTRIC: PRODUCT PORTFOLIO
  • TABLE 127. GENERAL ELECTRIC: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 128. VARIAN MEDICAL SYSTEMS, INC.: KEY EXECUTIVES
  • TABLE 129. VARIAN MEDICAL SYSTEMS, INC.: COMPANY SNAPSHOT
  • TABLE 130. VARIAN MEDICAL SYSTEMS, INC.: OPERATING SEGMENTS
  • TABLE 131. VARIAN MEDICAL SYSTEMS, INC.: PRODUCT PORTFOLIO
  • TABLE 132. VARIAN MEDICAL SYSTEMS, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 133. BRAINLAB: KEY EXECUTIVES
  • TABLE 134. BRAINLAB: COMPANY SNAPSHOT
  • TABLE 135. BRAINLAB: OPERATING SEGMENTS
  • TABLE 136. BRAINLAB: PRODUCT PORTFOLIO
  • TABLE 137. BRAINLAB: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 138. MEDTRONIC,: KEY EXECUTIVES
  • TABLE 139. MEDTRONIC,: COMPANY SNAPSHOT
  • TABLE 140. MEDTRONIC,: OPERATING SEGMENTS
  • TABLE 141. MEDTRONIC,: PRODUCT PORTFOLIO
  • TABLE 142. MEDTRONIC,: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 143. OLYMPUS CORPORATION: KEY EXECUTIVES
  • TABLE 144. OLYMPUS CORPORATION: COMPANY SNAPSHOT
  • TABLE 145. OLYMPUS CORPORATION: OPERATING SEGMENTS
  • TABLE 146. OLYMPUS CORPORATION: PRODUCT PORTFOLIO
  • TABLE 147. OLYMPUS CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 148. KARL STORZ ENDOSCOPY INDIA PVT. LTD.: KEY EXECUTIVES
  • TABLE 149. KARL STORZ ENDOSCOPY INDIA PVT. LTD.: COMPANY SNAPSHOT
  • TABLE 150. KARL STORZ ENDOSCOPY INDIA PVT. LTD.: OPERATING SEGMENTS
  • TABLE 151. KARL STORZ ENDOSCOPY INDIA PVT. LTD.: PRODUCT PORTFOLIO
  • TABLE 152. KARL STORZ ENDOSCOPY INDIA PVT. LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 153. STRYKER: KEY EXECUTIVES
  • TABLE 154. STRYKER: COMPANY SNAPSHOT
  • TABLE 155. STRYKER: OPERATING SEGMENTS
  • TABLE 156. STRYKER: PRODUCT PORTFOLIO
  • TABLE 157. STRYKER: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 158. HOLOGIC INC.: KEY EXECUTIVES
  • TABLE 159. HOLOGIC INC.: COMPANY SNAPSHOT
  • TABLE 160. HOLOGIC INC.: OPERATING SEGMENTS
  • TABLE 161. HOLOGIC INC.: PRODUCT PORTFOLIO
  • TABLE 162. HOLOGIC INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL IMAGE-GUIDED BIOPSY MARKET SEGMENTATION
  • FIGURE 2. GLOBAL IMAGE-GUIDED BIOPSY MARKET
  • FIGURE 3. SEGMENTATION IMAGE-GUIDED BIOPSY MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN IMAGE-GUIDED BIOPSY MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALIMAGE-GUIDED BIOPSY MARKET
  • FIGURE 11. IMAGE-GUIDED BIOPSY MARKET SEGMENTATION, BY BY TECHNOLOGY
  • FIGURE 12. IMAGE-GUIDED BIOPSY MARKET FOR X- RAY, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 13. IMAGE-GUIDED BIOPSY MARKET FOR ULTRASOUND, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 14. IMAGE-GUIDED BIOPSY MARKET FOR MAMMOGRAPHY, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 15. IMAGE-GUIDED BIOPSY MARKET FOR CT, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 16. IMAGE-GUIDED BIOPSY MARKET FOR MRI, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 17. IMAGE-GUIDED BIOPSY MARKET SEGMENTATION, BY BY PROCESS
  • FIGURE 18. IMAGE-GUIDED BIOPSY MARKET FOR FINE NEEDLES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 19. IMAGE-GUIDED BIOPSY MARKET FOR CORE NEEDLES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 20. IMAGE-GUIDED BIOPSY MARKET FOR VACUUM-ASSISTED BIOPSY, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 21. IMAGE-GUIDED BIOPSY MARKET SEGMENTATION, BY BY END USER
  • FIGURE 22. IMAGE-GUIDED BIOPSY MARKET FOR HOSPITALS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 23. IMAGE-GUIDED BIOPSY MARKET FOR AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 24. IMAGE-GUIDED BIOPSY MARKET FOR CLINICS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 25. IMAGE-GUIDED BIOPSY MARKET FOR RESEARCH AND ACADEMIC INSTITUTES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 26. TOP WINNING STRATEGIES, BY YEAR, 2020-2022*
  • FIGURE 27. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2020-2022*
  • FIGURE 28. TOP WINNING STRATEGIES, BY COMPANY, 2020-2022*
  • FIGURE 29. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 30. COMPETITIVE DASHBOARD
  • FIGURE 31. COMPETITIVE HEATMAP: IMAGE-GUIDED BIOPSY MARKET
  • FIGURE 32. Top player positioning, 2022
  • FIGURE 33. KONINKLIJKE PHILIPS N.V.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 34. KONINKLIJKE PHILIPS N.V.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 35. KONINKLIJKE PHILIPS N.V.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 36. SIEMENS HEALTHCARE GMBH: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 37. SIEMENS HEALTHCARE GMBH: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 38. SIEMENS HEALTHCARE GMBH: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 39. ANALOGIC CORPORATION: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 40. ANALOGIC CORPORATION: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 41. ANALOGIC CORPORATION: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 42. GENERAL ELECTRIC: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 43. GENERAL ELECTRIC: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 44. GENERAL ELECTRIC: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 45. VARIAN MEDICAL SYSTEMS, INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 46. VARIAN MEDICAL SYSTEMS, INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 47. VARIAN MEDICAL SYSTEMS, INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 48. BRAINLAB: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 49. BRAINLAB: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 50. BRAINLAB: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 51. MEDTRONIC,: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 52. MEDTRONIC,: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 53. MEDTRONIC,: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 54. OLYMPUS CORPORATION: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 55. OLYMPUS CORPORATION: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 56. OLYMPUS CORPORATION: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 57. KARL STORZ ENDOSCOPY INDIA PVT. LTD.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 58. KARL STORZ ENDOSCOPY INDIA PVT. LTD.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 59. KARL STORZ ENDOSCOPY INDIA PVT. LTD.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 60. STRYKER: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 61. STRYKER: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 62. STRYKER: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 63. HOLOGIC INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 64. HOLOGIC INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 65. HOLOGIC INC.: REVENUE SHARE, BY REGION, 2032 (%)

 
 
With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

  • Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
  • Technologically sophisticated and reliable insights through well audited and veracious research methodology
  • Sovereign research proceeds that present a tangible depiction of marketplace


With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, web-casts and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast


Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develops analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth and forecasts


Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

  • Chief executives and VPs of leading corporations specific to industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)


Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

PURCHASE OPTIONS

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : +44-845-528-1300
Email : help@alliedmarketresearch.com

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Enquiry Now

Purchase Full Report of
Image-guided Biopsy Market

Start reading.
This Report and over 68,247+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,690
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
  • Data Pack
  • $3,930
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Single User
  • $5,820
  • Restricted to one authorized user
  • One print only
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Five Users
  • $6,540
  • Limited to five authorized users
  • Print upto five copies
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Enterprise
    License/PDF

  • $9,870
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Library
    Membership

  • $999 $ 1,175
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

RELATED REPORTS
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers